<unk> s are targeted therapies that act on tumors with activating alterations in the<unk>  proto-oncogene, such as point mutations or fusions. They fall under the category of the tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of cancer cells. Existing molecules fall in two main categories: the older multikinase inhibitors and the more recent selective inhibitors. Although<unk>  alterations are found at low frequency in a broad range of tumors, the three main indications for<unk> s today are non-small cell lung cancer (which harbor<unk>  fusions at a frequency of 1-2%), medullary thyroid cancer (MTC, with activating<unk>  mutations in 25% of cases) and papillary thyroid cancer (PTC, with up to 80% prevalence of fusions depending on the region). As of 2020, up to 48 fusion partners have been catalogued in NSCLC rearrangements, with KIF5B and CCDC6 being the most prevalent. At least 10 different fusion variants have been described for KIF5B-RET, each with different breakpoints within the partner gene, but unclear clinical impact as of 2018.
RET inhibitor
MEK inhibitor
C-Met inhibitor
CDK inhibitor
CXCR4 antagonist
Growth factor receptor inhibitor
MTOR inhibitors
Histone deacetylase inhibitor